X

Trial Profile

Phase I/Ib Study of Crenolanib With Ramucirumab and Paclitaxel as Second Line Therapy for Advanced Esophagogastric Adenocarcinoma

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 14 Mar 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Crenolanib (Primary) ; Paclitaxel; Ramucirumab
Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
Focus Adverse reactions; Therapeutic Use
Sponsors AROG Pharmaceuticals

Most Recent Events

01 Feb 2022 Status changed from recruiting to discontinued as per results published in the Cancer Chemotherapy and Pharmacology
01 Feb 2022 Results published in the Cancer Chemotherapy and Pharmacology
01 Jul 2019 Planned End Date changed from 1 Apr 2019 to 1 Aug 2020.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com